Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...